Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article by Haiyan Zeng, et al. on X:
“Hippocampal-Avoidance PCI: Game-Changer or Cognitive Mirage?
Objective:
- Evaluate the impact of HA-PCI on self-reported cognitive function and metastases risk in SCLC.
Methods:
- Pooled data from two phase III RCTs (NCT01780675 & PREMER).
- Randomized comparison: Standard PCI vs. HA-PCI.
Results:
- No significant cognitive benefit with HA-PCI (p=0.52).
- No increased risk of brain metastases (p=0.9).
- At 4 months, HA-PCI showed cognitive impairment (p*=0.04), but this effect was not sustained over time.
Conclusion:
- HA-PCI is safe but does Not significantly protect cognition.
- Future PCI strategies should explore neuroprotective agents to enhance cognitive outcomes!”
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
Authors: Haiyan Zeng, et al.
